A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Clinical trial NCT02431208 · COMPLETED
Trial details
- NCT number
- NCT02431208
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-22
- Primary completion
- 2021-03-19
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.